Last reviewed · How we verify
CGB-500 with 0.5% tofacitinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
CGB-500 with 0.5% tofacitinib (CGB-500 with 0.5% tofacitinib) — CAGE Bio Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CGB-500 with 0.5% tofacitinib TARGET | CGB-500 with 0.5% tofacitinib | CAGE Bio Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CGB-500 with 0.5% tofacitinib CI watch — RSS
- CGB-500 with 0.5% tofacitinib CI watch — Atom
- CGB-500 with 0.5% tofacitinib CI watch — JSON
- CGB-500 with 0.5% tofacitinib alone — RSS
Cite this brief
Drug Landscape (2026). CGB-500 with 0.5% tofacitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/cgb-500-with-0-5-tofacitinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab